Role of Adjuvant Chemotherapy on Recurrence and Survival in Patients with Resected Ampulla of Vater Carcinoma

Overview

Journal World J Gastrointest Oncol

Publisher Baishideng Publishing Group

Date 2023 May 1

PMID 37123060

Authors

Se Jun Park

Kabsoo Shin

In-Ho Kim

Tae Ho Hong

Younghoon Kim

Myung-Ah Lee

Affiliations

Soon will be listed here.

Abstract

Background: Owing to rarity of disease and lack of prospective studies, data supporting the role of adjuvant chemotherapy in ampulla of Vater (AoV) carcinoma is limited.

Aim: To evaluate whether adjuvant chemotherapy cases for AoV carcinoma had better disease-free survival (DFS) rates than cases of observation following curative surgery.

Methods: We retrospectively analyzed the association between adjuvant chemotherapy and DFS and overall survival (OS) in patients with stage IBIII AoV carcinoma who underwent curative surgical resection. Fluorouracil-based adjuvant chemotherapy was administered after surgery at the discretion of the physician. Adjusted multivariate regression models were used to evaluate the association between adjuvant chemotherapy and survival outcomes.

Results: Of the total 104 patients who underwent curative surgery, 52 received adjuvant chemotherapy. Multivariate analysis revealed that higher histologic grade [hazard ratio (HR) = 2.24, = 0.046], advanced tumor stage (HR = 1.85, = 0.030), and vascular invasion (HR = 2.14, = 0.010) were associated with shorter DFS. Adjuvant chemotherapy improved DFS compared to the observation group (HR = 0.50, = 0.015) and tended to be associated with a longer OS, although the difference was not statistically significant (HR = 0.58, = 0.098).

Conclusion: Among patients with resected AoV carcinoma, the adjuvant chemotherapy group was not associated with a significant survival benefit compared to the observation group. However, on multivariate analysis adjusting for prognostic factors, adjuvant chemotherapy following surgery was an independent prognostic factor for DFS in patients with resected AoV carcinoma. Further studies are needed to investigate the effectiveness of adjuvant chemotherapy according to histologic phenotype.

References

Kim W, Choi D, Choi S, Heo J, You D, Lee H . Clinical significance of pathologic subtype in curatively resected ampulla of vater cancer. J Surg Oncol. 2011; 105(3):266-72. DOI: 10.1002/jso.22090. View

Sessa F, Furlan D, Zampatti C, Carnevali I, Franzi F, Capella C . Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability. Virchows Arch. 2007; 451(3):649-57. DOI: 10.1007/s00428-007-0444-1. View

Grothey A, Sobrero A, Shields A, Yoshino T, Paul J, Taieb J . Duration of Adjuvant Chemotherapy for Stage III Colon Cancer. N Engl J Med. 2018; 378(13):1177-1188. PMC: 6426127. DOI: 10.1056/NEJMoa1713709. View

Sikora S, Balachandran P, Dimri K, Rastogi N, Kumar A, Saxena R . Adjuvant chemo-radiotherapy in ampullary cancers. Eur J Surg Oncol. 2005; 31(2):158-63. DOI: 10.1016/j.ejso.2004.08.013. View

Bonet M, Rodrigo A, Vazquez S, Carrizo V, Vilardell F, Mira M . Adjuvant therapy for true ampullary cancer: a systematic review. Clin Transl Oncol. 2020; 22(8):1407-1413. DOI: 10.1007/s12094-019-02278-6. View

Neoptolemos J, Moore M, Cox T, Valle J, Palmer D, McDonald A . Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA. 2012; 308(2):147-56. DOI: 10.1001/jama.2012.7352. View

Chang D, Jamieson N, Johns A, Scarlett C, Pajic M, Chou A . Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater. J Clin Oncol. 2013; 31(10):1348-56. DOI: 10.1200/JCO.2012.46.8868. View

Conroy T, Hammel P, Hebbar M, Abdelghani M, Wei A, Raoul J . FOLFIRINOX or Gemcitabine as Adjuvant Therapy for Pancreatic Cancer. N Engl J Med. 2018; 379(25):2395-2406. DOI: 10.1056/NEJMoa1809775. View

Westgaard A, Tafjord S, Farstad I, Cvancarova M, Eide T, Mathisen O . Pancreatobiliary versus intestinal histologic type of differentiation is an independent prognostic factor in resected periampullary adenocarcinoma. BMC Cancer. 2008; 8:170. PMC: 2430209. DOI: 10.1186/1471-2407-8-170. View

10.

Valle J, Wasan H, Palmer D, Cunningham D, Anthoney A, Maraveyas A . Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010; 362(14):1273-81. DOI: 10.1056/NEJMoa0908721. View

11.

Kim J, Jeong J, Ryoo B, Kim K, Chang H, Oh D . Adjuvant Chemotherapy for Resected Ampulla of Vater Carcinoma: Retrospective Analysis of 646 Patients. Cancer Res Treat. 2020; 53(2):424-435. PMC: 8053873. DOI: 10.4143/crt.2020.953. View

12.

Kim H, Jang J, Yoon Y, Park S, Kwon W, Kim S . Does adjuvant treatment improve prognosis after curative resection of ampulla of Vater carcinoma? A multicenter retrospective study. J Hepatobiliary Pancreat Sci. 2020; 27(10):721-730. DOI: 10.1002/jhbp.801. View

13.

Ashfaq A, Pockaj B, Gray R, Halfdanarson T, Wasif N . Nodal counts and lymph node ratio impact survival after distal pancreatectomy for pancreatic adenocarcinoma. J Gastrointest Surg. 2014; 18(11):1929-35. DOI: 10.1007/s11605-014-2566-5. View

14.

Ahn D, Bekaii-Saab T . Ampullary cancer: an overview. Am Soc Clin Oncol Educ Book. 2014; :112-5. PMC: 4966534. DOI: 10.14694/EdBook_AM.2014.34.112. View

15.

Bhatia S, Miller R, Haddock M, Donohue J, Krishnan S . Adjuvant therapy for ampullary carcinomas: the Mayo Clinic experience. Int J Radiat Oncol Biol Phys. 2006; 66(2):514-9. DOI: 10.1016/j.ijrobp.2006.04.018. View

16.

Huebner M, Kendrick M, Reid-Lombardo K, Que F, Therneau T, Qin R . Number of lymph nodes evaluated: prognostic value in pancreatic adenocarcinoma. J Gastrointest Surg. 2012; 16(5):920-6. DOI: 10.1007/s11605-012-1853-2. View

17.

Neoptolemos J, Palmer D, Ghaneh P, Psarelli E, Valle J, Halloran C . Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017; 389(10073):1011-1024. DOI: 10.1016/S0140-6736(16)32409-6. View

18.

Primrose J, Fox R, Palmer D, Malik H, Prasad R, Mirza D . Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study. Lancet Oncol. 2019; 20(5):663-673. DOI: 10.1016/S1470-2045(18)30915-X. View

19.

Feng J, Wu R, Zhang G, Yang Z, Zhang L . Prognostic importance of numbers of retrieved lymph nodes and positive lymph nodes for ampulla of vater cancer (AVC) in 2347 patients from the Surveillance, Epidemiology, and End Results (SEER) database. PLoS One. 2021; 16(1):e0244987. PMC: 7810317. DOI: 10.1371/journal.pone.0244987. View

20.

Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C . Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009; 27(19):3109-16. DOI: 10.1200/JCO.2008.20.6771. View